
    
      Endometrial assessments are proposed following three month and then nine month treatment with
      metformin; expression of specified markers at respective time points will be compared to
      baseline.

      Visit 1: Screening

        -  Signed informed consent

        -  Comprehensive history intake

        -  Physical exam: Vital signs, height, weight, waist circumferences, waist : hip ratio

        -  Urine pregnancy test

        -  Subjects provided with a 10 day supply of vaginal progesterone and EMBx will be
           scheduled between days 6-8 of progesterone use.

      Visit 2: Baseline

        -  Urine pregnancy test

        -  Endometrium thickness will be measured via transvaginal ultrasound

        -  EMBx: sample of endometrial tissue will be sent for histopathology to rule out
           endometrial hyperplasia or cancer

        -  20cc blood

        -  Metformin prescription and dispensing will be as per clinical care.

        -  Women will be advised to use barrier method of contraception (ie; condoms, contraceptive
           jellies or foam, sponge, diaphragm, or cervical cap) for the duration of the study.

      Visits 3 and 5 (Weeks 8-10 and 30-34, respectively)

        -  Urine pregnancy test

        -  A 10 day course of vaginal progesterone to allow scheduling of EMBx's time points
           specified under visit 1

      Visits 4 and 6 (Weeks 12 ± 1 week and 36 ± 1 week respectively)

      - The procedure specified for baseline (Visit 2) will be repeated.
    
  